1. Search results in the navigational tree (All hits)
All the results are highlighted by color in the navigational tree
(at the left-hand side) and remain so until you click on a not highlighted menu item and
thus return to the usual content navigation.
In addition, you can browse through the search
results consecutively by pressing the navigational buttons
(
<
1 of
15
>).
Within the text the search
result is highlighted by color.
2. Search results by relevance (Top 5)
Following is a list of the 5 most important hits ranked by relevance.
Hint: In the
Help you will find explanations about using search operators in order to conduct an extended search.
[...] from the Merck Serono division to the Consumer Health division. A detailed presentation of the resulting disclosure changes in segment reporting can be found in the information on Segment Reporting. Amortization of intangible assets (excluding software), which was previously disclosed in a separate line in the income statement, was allocated to the corresponding functional costs in the third quarter of 2014. This has been done to ensure improved comparability of the income statement of the Merck Group with other companies. The amortization relates in particular to intangible assets recognized within the scope of the purchase price allocations for the acquisitions [...]
[...] revenues 2,936.4 2,751.8 6.7 8,464.4 8,353.4 1.3 Sales 2,905.6 2,659.5 9.3 8,315.0 8,063.8 3.1 Operating result (EBIT) 428.9 481.8 –11.0 1,338.2 1,346.6 –0.6 Margin (% of sales) 14.8 18.1 16.1 16.7 EBITDA 781.5 796.4 –1.9 2,318.7 2,343.4 –1.1 Margin (% of sales) 26.9 29.9 27.9 29.1 EBITDA pre one-time items 856.6 830.7 3.1 2,509.4 2,458.1 2.1 Margin (% of sales) 29.5 31.2 30.2 30.5 Earnings per share (€)1 0.57 0.78 –26.9 2.02 2.12 –4.7 Earnings per share pre one-time items (€)1 1.15 1.15 – 3.46 3.33 3.9 Business free cash flow 614.1 852.9 –28.0 1,930.4 2,229.5 –13.4 Development of sales and results of operations In the third quarter of 2014, [...]
XLS Performance Materials | Key figures € million Q3 – 2014 Q3 – 2013 Change in % Jan.–Sept. 2014 Jan.–Sept. 2013 Change in % Total revenues 576.1 406.7 41.7 1,484.8 1,260.5 17.8 Sales 576.1 406.5 41.7 1,484.0 1,258.9 17.9 Operating result (EBIT) 152.1 176.6 –13.9 441.3 519.3 –15.0 Margin (% of sales) 26.4 43.5 29.7 41.3 EBITDA 217.6 202.2 7.6 574.5 610.6 –5.9 Margin (% of sales) 37.8 49.7 38.7 48.5 EBITDA pre one-time items 242.9 196.8 23.4 655.7 613.2 6.9 Margin (% of sales) 42.2 48.4 44.2 48.7 Business free cash flow 166.9 219.9 –24.1 511.8 620.8 –17.6 Development of sales and results of operations In the third quarter of 2014, sales of the [...]
XLS Merck Millipore | Key figures € million Q3 – 2014 Q3 – 2013 Change in % Jan.–Sept. 2014 Jan.–Sept. 2013 Change in % Total revenues 664.4 645.5 2.9 1,986.3 1,988.8 –0.1 Sales 660.8 639.0 3.4 1,976.0 1,974.0 0.1 Operating result (EBIT) 71.7 66.6 7.7 233.9 211.3 10.7 Margin (% of sales) 10.9 10.4 11.8 10.7 EBITDA 149.6 144.7 3.4 463.7 444.4 4.3 Margin (% of sales) 22.6 22.6 23.5 22.5 EBITDA pre one-time items 160.5 157.2 2.1 495.9 475.0 4.4 Margin (% of sales) 24.3 24.6 25.1 24.1 Business free cash flow 108.5 139.0 –21.9 288.4 376.8 –23.4 Development of sales and results of operations In the third quarter, the Merck Millipore division again posted [...]
[...] into account negative foreign exchange effects of approximately 3% compared to the previous year and resulting from a decline in the value of the Japanese yen and especially Latin American currencies. As a result of the significant decline in the value of the euro against the U.S. dollar in the third quarter of 2014, we expect for the full year 2014 a U.S. dollar-euro exchange rate that is approximately at the previous year’s level. Based on business performance in the first three quarters of 2014, Merck reiterates its forecast for EBITDA pre one-time items for the full year 2014. The planned efficiency increases should be able to offset the effects of the [...]
